Judie Goodman, DO
Hematology & Oncology · Pontiac, MINPI 1003852732
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,499 and has fallen 98.3% since, to $26 in 2024.
Across 114 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$331
- Novartis$214
- Genentech USA, Inc.$191
- Merck$109
- AstraZeneca$105
- Gilead$99
- plus $976 from 26 others
Across 1 payment — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10K
What the payments were for
- Food & beverage$1,86292%
- Education$1648%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 12 | $331 |
| Novartis | 15 | $214 |
| Genentech USA, Inc. | 16 | $191 |
| Merck | 7 | $109 |
| AstraZeneca(2 entities) | 5 | $105 |
| Gilead(2 entities) | 6 | $99 |
| Taiho Oncology, Inc. | 5 | $89 |
| Foundation Medicine, Inc. | 2 | $71 |
| Pfizer | 5 | $70 |
| Lilly USA, LLC | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 4 | $59 |
| Exelixis Inc. | 3 | $57 |
| Bristol Myers Squibb | 2 | $52 |
| Sanofi | 3 | $49 |
| Johnson & Johnson | 3 | $46 |
| Astellas Pharma US Inc | 3 | $43 |
| Seagen Inc. | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $28 |
| AMAG Pharmaceuticals, Inc. | 2 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Boehringer Ingelheim | 1 | $26 |
| Puma Biotechnology, Inc. | 2 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Bayer | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Sobi, Inc | 1 | $18 |
| Shire North American Group Inc | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Innate Pharma, Inc | 1 | $14 |
| Tersera Therapeutics LLC | 1 | $13 |
How this compares
$2,026 in reported general payments places this provider in the 55th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $27,769 |
| Exemestane | 63 | $8,024 |
| Letrozole | 110 | $7,999 |
| Anastrozole | 64 | $2,765 |
| Hydroxyurea | 22 | $872 |
| Tamoxifen Citrate | 24 | $863 |
| Prochlorperazine Maleate | 14 | $376 |
| Alendronate Sodium | 36 | $368 |
| Ondansetron Hcl | 23 | $208 |
| Citalopram HbrCitalopram Hydrobromide | 15 | $98 |
| Prednisone | 22 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $70 | $27,76926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Pontiac
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
- Hadeel AssadDetroit$80K
- Andrew MuskovitzSouthfield$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.